CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Bavencio for metastatic Merkel Cell Carcinoma – Details

Project Number PC0124-000
Brand Name Bavencio
Generic Name Avelumab
Strength 20 mg/mL
Tumour Type Skin & Melanoma
Indication metastatic Merkel Cell Carcinoma
Funding Request For the treatment of mMCC in previously treated adults
Review Status Complete
Pre Noc Submission Yes
NOC Date December 18, 2017
Manufacturer EMD Serono - Pfizer Alliance
Sponsor EMD Serono - Pfizer Alliance
Submission Date October 10, 2017
Submission Deemed Complete October 17, 2017
Submission Type Initial
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ October 24, 2017
Check-point meeting December 4, 2017
pERC Meeting February 15, 2018
Initial Recommendation Issued March 2, 2018
Feedback Deadline ‡ March 16, 2018
Final Recommendation Issued March 21, 2018
Notification to Implement Issued April 6, 2018
Therapeutic Area metastatic Merkel Cell Carcinoma (mMCC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.